Teva share price struggles to recover following $6 billion market loss
The financial results were actually positive, at the higher end of analysts' forecasts, but profit guidance for 2025 ...
Nurix Therapeutics: A Story To Monitor
Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...
European shares tipped to soar as US investors pile in - experts reveal the cheap stocks they would buy
Where could be the top place to invest this spring? Europe. That's according to the latest edition of the hugely influential ...
Zacks.com on MSN15h
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
Sanofi SNY and partner Regeneron REGN announced that the FDA has accepted their supplemental biologics license application ...
Solid Bio surges after trial data for lead asset in Duchenne
Solid Biosciences (SLDB) stock surges after strong Phase 1/2 data for its Duchenne therapy SGT-003. Read more here.
Pharmaceutical Technology17h
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
As Sanofi and Regeneron await the FDA decision, a legal dispute between the partners over commercialisation details continues ...
FDA Approves Sanofi's Merilog As First Rapid-Acting Insulin Biosimilar Product For Diabetes
Sanofi's Merilog wins FDA approval as the first rapid-acting insulin biosimilar to Novolog, offering a new option for diabetes management.
Regeneron, Sanofi announce Dupixent sBLA accepted for priority review by FDA
Regeneron (REGN) and Sanofi (SNY) announced that the FDA has accepted for priority review the supplemental biologics license application for ...
Valeo Financial Advisors LLC Sells 8,976 Shares of Sanofi (NASDAQ:SNY)
Valeo Financial Advisors LLC decreased its holdings in Sanofi (NASDAQ:SNY – Free Report) by 62.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The fund ...